Treatment of hypercalcemia of malignancy with intravenous etidronate

A controlled, multicenter study

Frederick R. Singer, Paul S. Ritch, Thomas E. Lad, Q. Scott Ringenberg, Joan H. Schiller, Robert R. Recker, Elisabeth Ryzen, Claude S. Arnaud, Michael D. Draper, Gordon J. Strewler, John M. Bennett, Joanne R. Carignan, Craig S. McCune, Raman Qazi, Patrick J. Byrne, Peder Charles, Claus Hasling, Leif Mosekilde, Ronald C. DeConti, Gregory R. Harper & 25 others John Horton, John C. Ruckdeschel, Alexander S. Spiers, Lee M. Zehngebot, David S. Ettinger, Martin D. Abeloff, Michael D. Green, Howard S. Hochster, Harold A. Harvey, Allan Lipton, Mary A. Simmonds, Subhash Kukreja, Daniel Shevrin, Michael R. McClung, Nancy Kane-Johnson, Eric S. Orwoll, Lawrence C. Panasci, Walter A. Brzezinski, Tom Anderson, Marjorie A. Vukelich, Al B. Benson, Thomas E. Davis, James K. Willson, Manuel Fernandez, Robert K. Rude

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatment-related deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone In controlling hypercalcemia of malignancy. (Arch Intern Med. 1991;151-471-476).

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalArchives of Internal Medicine
Volume151
Issue number3
StatePublished - Mar 1991

Fingerprint

Etidronic Acid
Hypercalcemia
Multicenter Studies
Neoplasms
Diuresis
Therapeutics
Calcium
Serum
Double-Blind Method
Intravenous Infusions
Albumins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Singer, F. R., Ritch, P. S., Lad, T. E., Ringenberg, Q. S., Schiller, J. H., Recker, R. R., ... Rude, R. K. (1991). Treatment of hypercalcemia of malignancy with intravenous etidronate: A controlled, multicenter study. Archives of Internal Medicine, 151(3), 471-476.

Treatment of hypercalcemia of malignancy with intravenous etidronate : A controlled, multicenter study. / Singer, Frederick R.; Ritch, Paul S.; Lad, Thomas E.; Ringenberg, Q. Scott; Schiller, Joan H.; Recker, Robert R.; Ryzen, Elisabeth; Arnaud, Claude S.; Draper, Michael D.; Strewler, Gordon J.; Bennett, John M.; Carignan, Joanne R.; McCune, Craig S.; Qazi, Raman; Byrne, Patrick J.; Charles, Peder; Hasling, Claus; Mosekilde, Leif; DeConti, Ronald C.; Harper, Gregory R.; Horton, John; Ruckdeschel, John C.; Spiers, Alexander S.; Zehngebot, Lee M.; Ettinger, David S.; Abeloff, Martin D.; Green, Michael D.; Hochster, Howard S.; Harvey, Harold A.; Lipton, Allan; Simmonds, Mary A.; Kukreja, Subhash; Shevrin, Daniel; McClung, Michael R.; Kane-Johnson, Nancy; Orwoll, Eric S.; Panasci, Lawrence C.; Brzezinski, Walter A.; Anderson, Tom; Vukelich, Marjorie A.; Benson, Al B.; Davis, Thomas E.; Willson, James K.; Fernandez, Manuel; Rude, Robert K.

In: Archives of Internal Medicine, Vol. 151, No. 3, 03.1991, p. 471-476.

Research output: Contribution to journalArticle

Singer, FR, Ritch, PS, Lad, TE, Ringenberg, QS, Schiller, JH, Recker, RR, Ryzen, E, Arnaud, CS, Draper, MD, Strewler, GJ, Bennett, JM, Carignan, JR, McCune, CS, Qazi, R, Byrne, PJ, Charles, P, Hasling, C, Mosekilde, L, DeConti, RC, Harper, GR, Horton, J, Ruckdeschel, JC, Spiers, AS, Zehngebot, LM, Ettinger, DS, Abeloff, MD, Green, MD, Hochster, HS, Harvey, HA, Lipton, A, Simmonds, MA, Kukreja, S, Shevrin, D, McClung, MR, Kane-Johnson, N, Orwoll, ES, Panasci, LC, Brzezinski, WA, Anderson, T, Vukelich, MA, Benson, AB, Davis, TE, Willson, JK, Fernandez, M & Rude, RK 1991, 'Treatment of hypercalcemia of malignancy with intravenous etidronate: A controlled, multicenter study', Archives of Internal Medicine, vol. 151, no. 3, pp. 471-476.
Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR et al. Treatment of hypercalcemia of malignancy with intravenous etidronate: A controlled, multicenter study. Archives of Internal Medicine. 1991 Mar;151(3):471-476.
Singer, Frederick R. ; Ritch, Paul S. ; Lad, Thomas E. ; Ringenberg, Q. Scott ; Schiller, Joan H. ; Recker, Robert R. ; Ryzen, Elisabeth ; Arnaud, Claude S. ; Draper, Michael D. ; Strewler, Gordon J. ; Bennett, John M. ; Carignan, Joanne R. ; McCune, Craig S. ; Qazi, Raman ; Byrne, Patrick J. ; Charles, Peder ; Hasling, Claus ; Mosekilde, Leif ; DeConti, Ronald C. ; Harper, Gregory R. ; Horton, John ; Ruckdeschel, John C. ; Spiers, Alexander S. ; Zehngebot, Lee M. ; Ettinger, David S. ; Abeloff, Martin D. ; Green, Michael D. ; Hochster, Howard S. ; Harvey, Harold A. ; Lipton, Allan ; Simmonds, Mary A. ; Kukreja, Subhash ; Shevrin, Daniel ; McClung, Michael R. ; Kane-Johnson, Nancy ; Orwoll, Eric S. ; Panasci, Lawrence C. ; Brzezinski, Walter A. ; Anderson, Tom ; Vukelich, Marjorie A. ; Benson, Al B. ; Davis, Thomas E. ; Willson, James K. ; Fernandez, Manuel ; Rude, Robert K. / Treatment of hypercalcemia of malignancy with intravenous etidronate : A controlled, multicenter study. In: Archives of Internal Medicine. 1991 ; Vol. 151, No. 3. pp. 471-476.
@article{364212227e3b4e4db16e6f210fc54617,
title = "Treatment of hypercalcemia of malignancy with intravenous etidronate: A controlled, multicenter study",
abstract = "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63{\%} (72/114) of etidronate-treated and 33{\%} (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24{\%} of the etidronate- and 7{\%} of the saline-treated patients responded to treatment. No serious side effects or treatment-related deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone In controlling hypercalcemia of malignancy. (Arch Intern Med. 1991;151-471-476).",
author = "Singer, {Frederick R.} and Ritch, {Paul S.} and Lad, {Thomas E.} and Ringenberg, {Q. Scott} and Schiller, {Joan H.} and Recker, {Robert R.} and Elisabeth Ryzen and Arnaud, {Claude S.} and Draper, {Michael D.} and Strewler, {Gordon J.} and Bennett, {John M.} and Carignan, {Joanne R.} and McCune, {Craig S.} and Raman Qazi and Byrne, {Patrick J.} and Peder Charles and Claus Hasling and Leif Mosekilde and DeConti, {Ronald C.} and Harper, {Gregory R.} and John Horton and Ruckdeschel, {John C.} and Spiers, {Alexander S.} and Zehngebot, {Lee M.} and Ettinger, {David S.} and Abeloff, {Martin D.} and Green, {Michael D.} and Hochster, {Howard S.} and Harvey, {Harold A.} and Allan Lipton and Simmonds, {Mary A.} and Subhash Kukreja and Daniel Shevrin and McClung, {Michael R.} and Nancy Kane-Johnson and Orwoll, {Eric S.} and Panasci, {Lawrence C.} and Brzezinski, {Walter A.} and Tom Anderson and Vukelich, {Marjorie A.} and Benson, {Al B.} and Davis, {Thomas E.} and Willson, {James K.} and Manuel Fernandez and Rude, {Robert K.}",
year = "1991",
month = "3",
language = "English (US)",
volume = "151",
pages = "471--476",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Treatment of hypercalcemia of malignancy with intravenous etidronate

T2 - A controlled, multicenter study

AU - Singer, Frederick R.

AU - Ritch, Paul S.

AU - Lad, Thomas E.

AU - Ringenberg, Q. Scott

AU - Schiller, Joan H.

AU - Recker, Robert R.

AU - Ryzen, Elisabeth

AU - Arnaud, Claude S.

AU - Draper, Michael D.

AU - Strewler, Gordon J.

AU - Bennett, John M.

AU - Carignan, Joanne R.

AU - McCune, Craig S.

AU - Qazi, Raman

AU - Byrne, Patrick J.

AU - Charles, Peder

AU - Hasling, Claus

AU - Mosekilde, Leif

AU - DeConti, Ronald C.

AU - Harper, Gregory R.

AU - Horton, John

AU - Ruckdeschel, John C.

AU - Spiers, Alexander S.

AU - Zehngebot, Lee M.

AU - Ettinger, David S.

AU - Abeloff, Martin D.

AU - Green, Michael D.

AU - Hochster, Howard S.

AU - Harvey, Harold A.

AU - Lipton, Allan

AU - Simmonds, Mary A.

AU - Kukreja, Subhash

AU - Shevrin, Daniel

AU - McClung, Michael R.

AU - Kane-Johnson, Nancy

AU - Orwoll, Eric S.

AU - Panasci, Lawrence C.

AU - Brzezinski, Walter A.

AU - Anderson, Tom

AU - Vukelich, Marjorie A.

AU - Benson, Al B.

AU - Davis, Thomas E.

AU - Willson, James K.

AU - Fernandez, Manuel

AU - Rude, Robert K.

PY - 1991/3

Y1 - 1991/3

N2 - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatment-related deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone In controlling hypercalcemia of malignancy. (Arch Intern Med. 1991;151-471-476).

AB - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatment-related deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone In controlling hypercalcemia of malignancy. (Arch Intern Med. 1991;151-471-476).

UR - http://www.scopus.com/inward/record.url?scp=0025974180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025974180&partnerID=8YFLogxK

M3 - Article

VL - 151

SP - 471

EP - 476

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -